Finance

Lists
Why is ENGN down 2.02%?
Dive Deeper
ENGN:NASDAQ
enGene Therapeutics Inc
$ 1.94
-2.02%
(-0.040) 1D
$ 1.91
-1.55% (-0.030)
After hours
Closed: 10-р сарын 2, 16:00:01 (GMT-4)  ·   USD
All symbols
SymbolPriceChange% Change
Generating top insights for ENGN...
Open
$ 2.00
High
$ 2.02
Low
$ 1.93
Mkt. cap
130.01 сая
Avg. vol.
720.08 мян
Volume
692.75 мян
52-wk high
$ 12.25
52-wk low
$ 1.40
EPS
-$ 2.08
Beta
-0.29
Shares outstanding
67.02 сая
No. of employees
82
Open
$ 2.00
High
$ 2.02
Low
$ 1.93
Mkt. cap
130.01 сая
Avg. vol.
720.08 мян
Volume
692.75 мян
52-wk high
$ 12.25
52-wk low
$ 1.40
EPS
-$ 2.08
Beta
-0.29
Shares outstanding
67.02 сая
No. of employees
82
News stories
From web sources and news partners
About enGene Therapeutics Inc
CEO-
Employees82
Founded-
Headquarters-
Sector-
Websiteengene.com
Analyst ratings
Based on 5 analysts giving stock ratings to ENGN in the past 3 months
Hold
Buy
1
Hold
3
Sell
1
12-month forecast
Based on 5 Wall Street analysts offering 12 month price targets for ENGN in the last 3 months.
Highest
Current $ 1.94
$ 4.00 (+106.19%)
Average
$ 2.50 (+28.87%)
Lowest
$ 2.00 (+3.09%)
Analyst
Recommendation
Action
Price target
Projected
Date
David Dai
UBS
Hold
Reiterated
$ 2.00
+3.1%
09/16/2026
Mani Foroohar
Leerink Partners
Hold
Reiterated
$ 2.00
+3.1%
09/09/2026
Andres Y. Maldonado
H.C. Wainwright
Buy
Reiterated
$ 4.00
+106.2%
09/09/2026
Judah Frommer
Morgan Stanley
Sell
Maintained
-
-
08/12/2026
Yanan Zhu
Wells Fargo
Hold
Reiterated
$ 2.00
+3.1%
08/12/2026
Michael Schmidt
Guggenheim
Hold
Maintained
-
-
06/16/2026
Leland Gershell
Oppenheimer
Hold
Maintained
-
-
05/08/2026
Sean McCutcheon
Raymond James
Buy
Maintained
$ 4.00
+106.2%
05/08/2026
Allison Bratzel
Piper Sandler
Hold
Downgraded
$ 4.00
+106.2%
05/08/2026
Silvan Tuerkcan
Citizens JMP
Hold
Downgraded
-
-
05/08/2026
Unknown Analyst
WBB Securities
Buy
Initiated
$ 21.50
+1,008.2%
04/13/2026
Xin Yang NG‏
USmart Securities
Buy
Initiated
$ 21.50
+1,008.2%
04/13/2026
Xin Yang NG‏
USmart Securities
Buy
Initiated
$ 21.50
+1,008.2%
04/13/2026
Kelsey Goodwin
Piper Sandler
Buy
Maintained
-
-
03/26/2026
Maury Raycroft
Jefferies
Buy
Maintained
$ 28.00
+1,343.3%
02/25/2026
Previous reportsAll values in USD
Loading Previous Earnings...
Revenue
Net income
All values in USD
2025 оны 10-р сар
2026 оны 1-р сар
2026 оны 4-р сар
2026 оны 7-р сар
Revenue
-
-
-
-
Cost of goods sold
-
-
-
-
Cost of revenue
-
-
-
-
Research and development expenses
31.72 сая
22.26 сая
22.20 сая
20.09 сая
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
7.76 сая
8.93 сая
9.77 сая
13.92 сая
Operating expense
39.48 сая
31.18 сая
31.97 сая
34.01 сая
Total operating expenses
39.48 сая
31.18 сая
31.97 сая
34.01 сая
Operating income
-39.48 сая
-31.18 сая
-31.97 сая
-34.01 сая
Other non operating income
448.00 мян
-
-
-
EBT including unusual items
-38.38 сая
-29.75 сая
-30.23 сая
-32.50 сая
EBT excluding unusual items
-38.38 сая
-29.26 сая
-30.23 сая
-32.50 сая
Income tax expense
-497.00 мян
-
-
-
Effective tax rate
1.29%
-
-
-
Other operating expenses
-
-
-
-
Net income
-37.88 сая
-29.75 сая
-30.23 сая
-32.50 сая
Net profit margin
-
-
-
-
Earnings per share
-0.73
-0.44
-0.43
-0.47
Interest and investment income
1.98 сая
2.74 сая
2.66 сая
2.40 сая
Interest expense
-750.00 мян
-732.00 мян
-745.00 мян
-843.00 мян
Net interest expenses
1.22 сая
2.01 сая
1.92 сая
1.56 сая
Depreciation and amortization charges
-
-
-
-
EBITDA
-39.31 сая
-31.00 сая
-31.79 сая
-33.84 сая
Gain or loss from assets sale
-
-
-
-
Insider transactions
Insider transactions data is drawn from third-party sources. Learn more
Insider
Position
Type
Date
Shares
Amount
Page 1
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer
Google аппс